US Patent 7402314 In vivo activation of tumor-specific cytotoxic T cells

Patent 7402314 was granted and assigned to the scripps research institute on July, 2008 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

the scripps research institute

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

74023140

Date of Patent

July 22, 2008

Patent Application Number

092770640

Date Filed

March 26, 1999

Patent Citations Received

‌

US Patent 11965025 Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules

Patent Primary Examiner

‌

Shanon Foley

Patent abstract

The present invention relates to methods and compositions of activating cytotoxic T lymphocytes (CTLs) in vivo with specificity for particular antigenic peptides, and to methods and compositions of using activated CTLs in vivo for the treatment of a variety of disease conditions. In some preferred embodiments, the invention provides methods of employing a polypeptide of the amino acid sequence VMAGVGSPYV to specifically activating CTLs in subjects having a breast cancer overexpressing a Her-2/Neu protein, and methods of using the polypeptide to treat such subjects.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7402314 In vivo activation of tumor-specific cytotoxic T cells

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API